Pazopanib

VOTRIENT®

About VOTRIENT®

  1. Marketed by Novartis Pharmaceuticals Corporation (United States and European Union) and GlaxoSmithKline plc (Japan)
  2. Selective multi-targeted receptor tyrosine kinase inhibitor
  3. Treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma

Approvals

  1. First E.U. approval: June 14, 2010
  2. First U.S. approval: October 19, 2009

Constraint date forecast:

  1. Patent expiry: 2023 (United States)
  2. SPC expiries: 2025 (European Union)
  3. Patent expiry: 2027 (Japan)

The future of the generics landscape

Drugs to Watch

XARELTO®

Rivaroxaban, Rivaroxaban

心血管疾病

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team